Status:
COMPLETED
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
Lead Sponsor:
Pfizer
Conditions:
Coronary Disease
Coronary Arteriosclerosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of p...
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- angiographic evidence of coronary atherosclerosis
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid.
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT00134173
Start Date
October 1 2003
End Date
September 1 2006
Last Update
December 10 2007
Active Locations (146)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States
2
Pfizer Investigational Site
Mobile, Alabama, United States
3
Pfizer Investigational Site
Little Rock, Arkansas, United States
4
Pfizer Investigational Site
Fresno, California, United States